Pro Share Advisors LLC Nuvation Bio Inc. Transaction History

Pro Share Advisors LLC

$39.7 Billion
Q3 2024

A detailed history of Pro Share Advisors LLC transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 34,259 shares of NUVB stock, worth $99,351. This represents 0.0% of its overall portfolio holdings.

Number of Shares

34,259

Previous 19,513 75.57%

Holding current value

$99,351

Previous $56,000 39.29%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$2.3 - $3.83 $33,915 - $56,477	14,746 Added 75.57%	34,259 $78,000
Q2 2024 Aug 13, 2024	SELL	$2.58 - $3.69 $17,182 - $24,575	-6,660 Reduced 25.45%	19,513 $56,000
Q1 2024 May 08, 2024	BUY	$1.46 - $3.97 $3,010 - $8,186	2,062 Added 8.55%	26,173 $95,000
Q4 2023 Feb 14, 2024	BUY	$0.96 - $1.53 $4,978 - $7,934	5,186 Added 27.4%	24,111 $36,000
Q3 2023 Nov 13, 2023	SELL	$1.26 - $2.1 $26 - $44	-21 Reduced 0.11%	18,925 $25,000
Q2 2023 Aug 10, 2023	BUY	$1.56 - $1.84 $8,183 - $9,652	5,246 Added 38.29%	18,946 $34,000
Q1 2023 May 11, 2023	SELL	$1.6 - $2.48 $2,043 - $3,166	-1,277 Reduced 8.53%	13,700 $22,000
Q4 2022 Feb 02, 2023	BUY	$1.68 - $2.5 $3,606 - $5,367	2,147 Added 16.73%	14,977 $28,000
Q3 2022 Nov 04, 2022	SELL	$0.29 - $4.04 $71 - $989	-245 Reduced 1.87%	12,830 $30,000
Q2 2022 Aug 01, 2022	SELL	$3.24 - $5.85 $54,211 - $97,882	-16,732 Reduced 56.13%	13,075 $43,000
Q1 2022 May 10, 2022	SELL	$4.6 - $8.83 $22,650 - $43,478	-4,924 Reduced 14.18%	29,807 $157,000
Q4 2021 Feb 08, 2022	BUY	$7.75 - $10.05 $269,165 - $349,046	34,731 New	34,731 $295,000

Others Institutions Holding NUVB

# of Institutions

159

Shares Held

157M

Call Options Held

3.2K

Put Options Held

98.7K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $630M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Account

Pro Share Advisors LLC Nuvation Bio Inc. Transaction History